Financial Highlights - The company announced a dividend of $0.20 per share[5, 26], marking the 86th consecutive quarterly dividend[5] - The company reported a net income of $1 million, with earnings per share of $0.01[5] - The company's adjusted EBITDA was $112 million[5, 16] - The company's gross revenue reached $194 million[5, 16], which includes charter hire from all vessels and rigs[6] Contracted Revenue and Backlog - The company's fixed revenue backlog stands at $4.2 billion[5, 8, 26], with over two-thirds contracted to investment grade counterparties[5, 8] - The company extended three container vessels with Maersk for five years, adding approximately $225 million to the fixed backlog[5] - 71% of the company's contracted revenue is from container vessels[8] Operational Performance - The company's fleet utilization remains strong, with container vessels, car carriers, tanker vessels, and dry bulk vessels all reporting utilization rates at or near 100%[13] - The company's cash and cash equivalents at quarter end was $156 million[24, 26] Portfolio Composition - The company's portfolio includes 30 container vessels, 18 tanker vessels, 7 car carriers, 3 dry bulk vessels, and 2 energy assets[8] - The company's contracted revenue is diversified across various sectors, with container vessels accounting for 71%, tanker vessels for 11%, car carriers for 11%, and energy for 7%[8] Client Base - The company has a strong portfolio of industry-leading clients, including a world-leading chemical logistics company (29% of contracted revenue), a publicly listed investment grade shipping company (21% of contracted revenue), and other major players in the container shipping, energy, and automotive industries[11]

Financial Performance (Q2 2025) - Workhorse's sales, net of returns and allowances, for the three months ended June 30, 2025, were $5.7 million, compared to $0.8 million for the same period in 2024, representing an increase of $4.8 million[21] - Cost of sales for the three months ended June 30, 2025, was $13.1 million, compared to $7.3 million for the same period in 2024, an increase of $5.8 million[22] - Selling, general, and administrative expenses for the three months ended June 30, 2025, were $5.8 million, compared to $12.1 million for the same period in 2024, a decrease of $6.3 million[23] - Research and development expenses for the three months ended June 30, 2025, were $1.2 million, compared to $2.0 million for the same period in 2024, a decrease of $0.7 million[24] - As of June 30, 2025, Workhorse had $24.7 million in cash and cash equivalents, including restricted cash[25] Merger with Motiv Electric Trucks - Workhorse is undergoing a strategic merger with Motiv Electric Trucks to broaden the product portfolio and strengthen the financial position[34] - Motiv's controlling investor is expected to own approximately 62.5% of the combined company, while Workhorse shareholders are expected to own approximately 26.5%, and the senior secured lender approximately 11%[35] - The transaction is expected to bring in $45 million of added financing capacity upon closing[38] - The combined company is expected to achieve cost synergies of more than $20 million by the end of 2026[51] Strategic Priorities - Workhorse aims to complete the transaction with Motiv in Q4 2025, pending shareholder approvals and financing commitments[56]

Financial Highlights - Adecoagro's gross revenues for Q2 2025 were $392 million, a decrease of 1% compared to the same period last year[17] - Gross revenues for 6M25 reached $716 million, an increase of 10% compared to the same period last year[17] - Adjusted EBITDA for Q2 2025 was $55 million, a decrease of 60% compared to the same period last year[17] - Adjusted EBITDA for 6M25 was $91 million, a decrease of 60% compared to the same period last year[17] Segment Performance - Sugar, Ethanol & Energy - Sugar, Ethanol & Energy accounted for 77% of gross revenues in Q2 2025[17] - Sugar production decreased by 15% from 233,881 tons in Q2 2024 to 199,175 tons in Q2 2025[30] - Ethanol production decreased by 21% from 143,401 m3 in Q2 2024 to 98,756 m3 in Q2 2025[31] - Adjusted EBITDA for Sugar, Ethanol & Energy business decreased by 36% from $68,100 thousand in Q2 2024 to $106,886 thousand in Q2 2025[42] Farming Business - 296,057 hectares of Crops + Rice were harvested[52] - Soybean harvested area is 91,802 ha[52] - Raw milk production reached 93 million liters[52] - Farming segment experienced a significant decrease in financial performance, with profits dropping by 97% from $37,792 thousand in Q2 2024 to $1,081 thousand in Q2 2025[55] Capital Allocation - Net debt stood at $699 million[62] - 75% of debt is long term debt[63] - 70% of debt is in USD and 30% in BRL[65] - $45.2 million has been committed to shareholder distribution[71]

Financial Highlights - X Financial achieved a Return on Equity (ROE) of 24%[10] - The company has authorized a share buyback program of $115 million for 2025-2026, targeting approximately 5.8 million shares at around $20 per share, representing roughly 14% of the current float[14] - X Financial's trailing twelve months (TTM) net income is $243 million, resulting in a Price-to-Earnings (P/E) ratio of 2.5x, with a market capitalization of approximately $600 million[17] - The company projects a 30% volume growth guidance in FY25[17] Business Model and Performance - X Financial's loan facilitation business delivered over 45% Return on Invested Capital (ROIC) in Q1 2025[21] - Total net revenue increased by 65.6% from RMB 1,372,588 thousand in 2Q 2024 to RMB 2,273,123 thousand in 2Q 2025 (USD 317,316 thousand)[83] - Net income increased by 27.1% from RMB 415,303 thousand in 2Q 2024 to RMB 528,016 thousand in 2Q 2025 (USD 73,709 thousand)[83] Balance Sheet - Cash and equivalents increased by 17.1% from RMB 984,611 thousand on 12/31/2024 to RMB 1,152,990 thousand in 2Q 2025 (USD 160,951 thousand)[85] - Total assets increased by 15.8% from RMB 11,819,288 thousand on 12/31/2024 to RMB 13,687,855 thousand in 2Q 2025 (USD 1,910,751 thousand)[85] - Total equity increased by 11.0% from RMB 6,953,154 thousand on 12/31/2024 to RMB 7,720,902 thousand in 2Q 2025 (USD 1,077,797 thousand)[85]

Financial Performance - Medtronic reported Q1 FY26 revenue of $8.539 billion, a 6.7% increase compared to Q1 FY25, with organic revenue growth of 4.8%[24] - Adjusted diluted EPS was $1.26, a 2.4% increase year-over-year[24] - The company is raising FY26 EPS guidance and expects high-single digit EPS growth in FY27[15, 58] Segment Performance - Cardiovascular segment revenue reached $3.285 billion, with 7.0% organic growth[21, 40] - Cardiac Ablation Solutions experienced nearly 50% global growth, including over 70% US growth[15, 32, 39] - Neuroscience segment revenue was $2.416 billion, with 3.1% organic growth[21, 45] - Medical Surgical segment revenue totaled $2.083 billion, with 2.4% organic growth[21, 50] - Diabetes segment revenue was $721 million, with 7.9% organic growth[21, 55] Strategic Initiatives - Medtronic is executing strategic portfolio management, including Diabetes separation within 15 months[15, 55] - The company anticipates a net FY26 tariff impact of approximately $185 million, a decrease from the previous estimate of $200-350 million[15] Future Outlook - Medtronic expects revenue growth to accelerate in the second half of the fiscal year due to significant product launches[14, 31] - Cardiac Ablation Solutions is expected to grow even faster in Q2 and H2 due to PFA supply expansion[15]

Financial Performance - Total revenue for Q2 2025 reached $1880 million, compared to $1587 million in Q2 2024[28] - Adjusted Gross Margin for Q2 2025 was $1237 million, up from $1038 million in Q2 2024[28] - Net income for Q2 2025 was $439 million, significantly higher than the $160 million reported in Q2 2024[28] - Adjusted EBITDA for Q2 2025 was $633 million, compared to $493 million in Q2 2024[28] - Net Yield was $607 in Q2 2025, compared to $562 in Q2 2024[28] Bookings and Capacity - 2025 Advance Bookings reached $5600 million, showing a 21% growth[41] - 2026 Advance Bookings amounted to $3900 million, reflecting a 13% growth[43] - 96% of 2025 Capacity Passenger Cruise Days (PCD) have been sold[41] - 55% of 2026 Capacity Passenger Cruise Days (PCD) have been sold[43] Fleet and Expansion - The company has 85 River vessels, 12 Ocean ships, and 2 Expedition ships[19] - The company is expanding in destinations like the Nile, Mekong, and Brahmaputra rivers[22]

Financial Performance & Guidance - Opera achieved 17 consecutive quarters of Rule of 40 performance, driven by organic growth[11] - The company's 2025 revenue guidance is $591 million, representing a 23% growth[14] - The 2025 adjusted EBITDA guidance is $138 million, with a 23% margin[20, 21] - Q3 2025 revenue guidance is $148 million, representing 20% growth[89] - Since 2020, Opera has returned approximately $477 million to shareholders[16, 17, 98] User Base & Monetization - Opera has approximately 289 million average monthly active users (MAUs) in Q2 2025[12, 13] - Western markets account for 58 million MAUs[13] - ARPU has grown 3.1x over the last 4 years[18, 19] - Advertising accounts for 65% of revenue in Q2 2025, with 44% year-over-year growth[66, 69] - Search accounts for 35% of revenue in Q2 2025, with 11% year-over-year growth[66, 73] Opera GX - Opera GX has 33 million users[45] - Opera GX users represent 8% penetration of web users[52]

Fiscal Year 2025 Performance - Consolidated net revenue for Q4 FY25 was $262.9 million[13] - Supply Chain Services net revenue for Q4 FY25 reached $170 million, exceeding expectations[13] - Performance Services net revenue excluding Contigo Health for Q4 FY25 was $88 million, below the implied guidance[13] - Adjusted EBITDA excluding Contigo Health for Q4 FY25 was $71.1 million, surpassing expectations[13] - The company had cash flow from operations of $417.8 million for the fiscal year ended June 30, 2025[16] - Free cash flow was $180.5 million for the fiscal year ended June 30, 2025[17] Capital Allocation - The company repurchased $800 million of Class A common stock under the $1 billion share repurchase authorization[18] - Dividends of $77.4 million were paid to stockholders in fiscal year 2025[18] Fiscal Year 2026 Guidance - Total net revenue excluding Contigo Health is projected to be between $940 million and $1 billion[21] - Supply Chain Services revenue is expected to be between $590 million and $620 million[21] - Performance Services revenue excluding Contigo Health is guided to be between $350 million and $380 million[21]

A NEW FRONTIER FOR INTRANASAL DRUG DELIVERY Company Presentation – August 2025 A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE American 1 Experienced leadership team Strong IP protection to 2038 Forward Looking Statements This presentation of Nasus Pharma Ltd. contains "forward-looking statements" within the meaning of the Private Securities Litigati ...

Financial Performance - The company achieved strong earnings growth and stable loan growth[13] - Return on equity for the parent bank was 11.5%[15], exceeding the target of >11%[15], while the group's return on equity was 12.7%[15] - The core capital adequacy ratio was 17.72%[15], exceeding the target of >16.74%[15] - The cost/income ratio for the parent bank was 37.4%[15], below the target of <40%[15] - Net interest income increased to 350 million NOK[36] compared to 346 million NOK[36] in the previous year - Net profit for the first half of 2025 was 243 million NOK[36], compared to 182 million NOK[36] in the first half of 2024 Loan and Deposit Growth - Total lending increased by 5.8%[19] over the last 12 months - Total lending reached 35.566 billion NOK[19] as of June 30, 2025 - Customer deposits grew by 8.1%[29] over the last 12 months - Total deposits reached 19.065 billion NOK[27] as of June 30, 2025 Loan Portfolio - Personal market (PM) loans accounted for 74%[25] of the portfolio, while business market (BM) loans accounted for 26%[25]